Prognostic value of the expression of epithelial cell adhesion molecules in head and neck squamous cell carcinoma treated by definitive radiotherapy.
BerEP4
EpCAM
biomarker
head and neck squamous cell carcinoma
primary radiation therapy
Journal
Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611
Informations de publication
Date de publication:
22 Nov 2019
22 Nov 2019
Historique:
received:
17
04
2019
revised:
30
05
2019
pubmed:
31
7
2019
medline:
24
4
2020
entrez:
31
7
2019
Statut:
ppublish
Résumé
A reliable biomarker can contribute to appropriate treatment selection in the management of head and neck squamous cell carcinoma (HNSCC). Recently, epithelial cell adhesion molecule (EpCAM) was shown to have prognostic features in several malignancies. However, it remains to be elucidated whether EpCAM predicts prognosis of HNSCC after radiotherapy. Therefore, the prognostic potential of EpCAM in HNSCC patients treated by radiotherapy was investigated in this study. All HNSCCs patients examined between January 2013 and December 2015 were analyzed for the expression of EpCAM. One hundred HNSCC patients were identified who were treated by primary radiotherapy. Intense expression of EpCAM was found in 29 HNSCC patients. Two-year overall survival (OS) for patients with intense EpCAM expression was 62.2%, whereas it was 87.9% for those without (P = 0.011). In multivariate analysis, intense EpCAM expression was found to be an independent prognostic factors for OS (P = 0.036). Overall, EpCAM was found to be an independent prognostic factor for HNSCC.
Identifiants
pubmed: 31361893
pii: 5541555
doi: 10.1093/jrr/rrz053
pmc: PMC6873617
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p16
0
Epithelial Cell Adhesion Molecule
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
803-811Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.
Références
Br J Surg. 2013 Jan;100(2):252-60
pubmed: 23175431
BMC Cancer. 2006 Jun 23;6:165
pubmed: 16796747
Int J Clin Oncol. 2011 Feb;16(1):33-8
pubmed: 20842404
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
Histopathology. 2016 May;68(6):897-904
pubmed: 26401964
Cancer Res. 2002 Dec 15;62(24):7350-6
pubmed: 12499279
Radiother Oncol. 2010 Jun;95(3):371-80
pubmed: 20493569
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Am J Clin Pathol. 1998 Jan;109(1):85-9
pubmed: 9426522
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
Diagn Cytopathol. 1993 Oct;9(5):516-21
pubmed: 8287759
Pathol Int. 2016 Apr;66(4):210-7
pubmed: 27041736
Am J Pathol. 2007 Aug;171(2):386-95
pubmed: 17600130
Int J Gynecol Cancer. 2009 Jul;19(5):860-6
pubmed: 19574774
Laryngoscope. 2014 Nov;124(11):E431-6
pubmed: 25043563
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Cancer. 2002 Feb 1;94(3):713-22
pubmed: 11857304
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1017-23
pubmed: 19910141
Cancer. 2001 Aug 15;92(4):805-13
pubmed: 11550151
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
J Cancer Res Clin Oncol. 2015 Jan;141(1):177-84
pubmed: 25119987
Radiother Oncol. 2013 Sep;108(3):489-94
pubmed: 24060179
Cancer Res. 2009 Jul 15;69(14):5627-9
pubmed: 19584271
J Clin Oncol. 2003 Jan 1;21(1):92-8
pubmed: 12506176
J Clin Oncol. 1993 Oct;11(10):1873-8
pubmed: 8410112
Cancer Treat Rev. 2012 Feb;38(1):68-75
pubmed: 21576002
Nat Rev Cancer. 2001 Dec;1(3):233-40
pubmed: 11902578
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Clin Cancer Res. 2011 Oct 1;17(19):6262-71
pubmed: 21969383
J Natl Cancer Inst. 1996 Oct 16;88(20):1456-66
pubmed: 8841020
Gynecol Oncol. 2014 Mar;132(3):618-23
pubmed: 24486605
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Br J Cancer. 1995 Apr;71(4):826-30
pubmed: 7710950